

AMENDMENTS TO CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-137. (canceled)

138. (currently amended) A method of treating a ~~pathological condition characterized by involvement of the~~ condition or disorder associated with the activity of NK-1 receptor comprising:

administering to a mammal in need thereof, a therapeutically effective amount of at least one oligonucleotide or oligonucleotide analog which interferes with the function or production of NK-1 receptors; and,
utilizing said oligonucleotide or oligonucleotide analog of SEQ ID. No. 41 in said administering.

139. (previously presented) The method of claim 138, wherein said interference with said function or production of said NK-1 receptors involves at least one nucleic acid in the NK-1 receptor pathway.

140. (previously presented) The method of claim 139, wherein said nucleic acid is one or more selected from the group consisting of DNA, RNA, tRNA, mRNA, and rRNA.

141. (previously presented) The method of claim 138, wherein said oligonucleotide or oligonucleotide analog is one or more selected from the group consisting of DNA antisense

oligonucleotides and oligonucleotide analogs, RNA antisense oligonucleotides and oligonucleotide analogs, DNA sense oligonucleotides and oligonucleotide analogs, RNA sense oligonucleotides and oligonucleotide analogs, aptamers and ribozymes.

142. (previously presented)The method of claim 138, wherein said oligonucleotide or oligonucleotide analog is applied by intrathecal infusion to the spinal cord.

143. (previously presented)The method of claim 138, wherein the amount of said oligonucleotide or oligonucleotide analog that is administered is from 15 to 30 nanomoles per kilogram of body weight of said mammal.

144. (previously presented)The method of claim 138, wherein the amount of said oligonucleotide or oligonucleotide analog is from 20 to 25 nanomoles per kilogram of said mammal.

145. (previously presented)The method of claim 138, wherein the amount of said oligonucleotide or oligonucleotide analog that is administered is from 15 to 300 nanomoles of body weight of said mammal.

146. (previously presented)The method of claim 138, wherein the amount of said oligonucleotide or oligonucleotide analog that is administered is from 50 to 600 micograms per kilogram of body weight of said mammal.

147. (previously presented)The method of claim 138, wherein the amount of said oligonucleotide or oligonucleotide analog that is administered is from 200 to 400 micograms per kilogram of body weight of said mammal.

148. (previously presented) The method of claim 138, wherein the amount of said oligonucleotide or oligonucleotide analog that is administered is from 250 to 350 micograms per kilogram of body weight of said mammal.

149. (previously presented) The method of claim 138, wherein said oligonucleotide or oligonucleotide analog is administered via intravenous infusion.

150. (currently amended) The method of claim 138, wherein said ~~pathological condition or disorder~~ is one or more selected from the group consisting of ~~central aspects of chronic or acute pain and peripheral aspects of chronic or acute pain~~ dermatological disorders, immune disorders, autoimmune disorders, cardiovascular disorders, vascular disorders, gut inflammation, arthritis, airway disorders, neuropathic disorders, psychiatric disorders, and central nervous system disorders.

151. (new) The method of claim 138, wherein said condition or disorder is one or more selected from the group consisting of acute pain, acute inflammation, chronic pain, and chronic inflammation.